Larazotide Acetate vs PEG-MGF
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateAnabolic & IGF
PEG-MGF- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
- Half-Life
- Local gut action; minimal systemic exposure
- ~3 days (due to PEGylation)
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 200–400 mcg
- Frequency
- 3x daily
- 2–3x per week
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Extended half-life (~3 days) vs native MGF (minutes)
- Systemic muscle satellite cell activation via subcutaneous injection
- Promotes muscle fiber repair and hypertrophy throughout the body
- Enhanced recovery from intense training or muscle injury
- Synergistic with IGF-1 LR3 and growth hormone peptides
- Useful in sarcopenia, post-injury recovery, and athletic performance
- Single injection provides multi-day anabolic signaling
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Water retention and localized swelling
- Potential hypoglycemia at high doses
- Theoretical cancer growth risk (growth factor)
- Injection site reactions
- +1 more
- Stacks With
- —
- —